A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Status:
Completed
Trial end date:
2020-12-16
Target enrollment:
Participant gender:
Summary
This is a study to determine the clinical benefit (how well the drug works), safety and
tolerability of combining CDX-3379 and cetuximab. The study will enroll patients with
advanced head and neck squamous cell carcinoma who have previously received cetuximab and
progressed.